Plus, news about XyloCor, Pfizer, Evotech, Skyhawk Therapeutics, HepaRegeniX and Vyome:
Ideaya Biosciences’ $263M public offering: The South San Francisco, CA-based biotech said Tuesday it will sell more than seven million shares at $35 apiece in addition to pre-funded warrants. The offering is expected to close Thursday. — Ayisha Sharma
Immuneel Therapeutics raises $12M in Series A extension: The funds will be used to support the Indian CAR-T cell therapy company’s growth and expansion, according to an exclusive report by Entrackr, a news site that covers startups. Immuneel aims to bring cell and gene therapies for cancer to non-Western markets at a fraction of current prices. — Ayisha Sharma
XyloCor licenses catheter device for heart drugs: The company will use the device to help develop “catheter-based endocardial delivery” of its heart gene therapy, called XC001. XyloCor gave SmartCella an undisclosed upfront payment and is on the hook for milestones that, if all are reached, could total $130 million. — Max Gelman
Pfizer, Evotech partner on French R&D: The companies will initially focus on early discovery work for metabolic and infectious diseases, much of which will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse. Evotec will get research funding from Pfizer and is eligible for milestones and royalties, although financial terms were not disclosed. — Ayisha Sharma
Skyhawk Therapeutics’ Phase 1 Huntington’s data: The company said SKY-0515 induced an average 72% reduction of the mRNA for the huntingtin protein associated with the disease. The Phase 1 study assessed a 9 mg dose across two parts. Skyhawk tested multiple doses and said there was a dose response. The company plans to start a Phase 2 study early next year. — Max Gelman
HepaRegeniX secures €15M in Series C: The proceeds are expected to help advance the company’s liver regeneration candidate into a Phase 2a test. The asset, dubbed HRX-215, is a small molecule inhibitor of mitogen-activated protein kinase 4. The round was led by Vesalius Biocapital IV with support from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds. — Ayisha Sharma
Vyome rides reverse merger to Nasdaq: The company will go public by merging with ReShape Lifesciences and changing the ticker to $HIND. In conjunction with the merger, Vyome secured a $7.3 million private placement. — Max Gelman